How XellSmart’s expanding IND portfolio is shaping the emerging market for CNS cell therapies

XellSmart’s iPSC-derived neuron therapy enters MSA-P trials after FDA and NMPA clearances. Discover what this means for regenerative neurology.

XellSmart’s iPSC-derived neuron therapy enters MSA-P trials after FDA and NMPA clearances. Discover what this means for regenerative neurology.